189954-96-9 Usage
Description
Firocoxib is a selective cyclooxygenase-2 (COX-2) inhibitor, which is an enol ether that is the cyclopropylmethyl ether of 3-hydroxy-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2-one. It is a white solid and is used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in horses and dogs. The brand name for Firocoxib is Equioxx (Merial).
Uses
Used in Veterinary Medicine:
Firocoxib is used as an anti-inflammatory and analgesic agent for the control of pain and inflammation associated with osteoarthritis in horses and dogs. It is a selective COX-2 inhibitor, which means it specifically targets the COX-2 enzyme responsible for inflammation and pain without affecting the COX-1 enzyme, which is involved in normal physiological processes.
Used in Antimicrobial Applications:
Firocoxib is also used as an antibacterial agent in veterinary medicine. Its exact mechanism of action in this context is not provided in the materials, but it is likely that it contributes to the overall treatment and management of infections in animals.
Used in Osteoarthritis Treatment:
Firocoxib is used as a treatment for osteoarthritis in dogs and horses, helping to decrease lameness, induce analgesia, and improve the range of motion. It is administered at doses of 5 mg/kg per day for dogs and 0.1 mg/kg per day for horses.
Veterinary Drugs and Treatments
Firocoxib is indicated in dogs and horses for the control of pain
and inflammation associated with osteoarthritis. A chewable tablet
form for dogs and an oral paste for horses are available.
Like other NSAIDs, firocoxib can be useful for treating fever,
pain, and/or inflammation associated with other conditions, postsurgery,
trauma, etc.
Firocoxib may also be useful in other species, but information is
scant regarding its safety and efficacy. One study in cats (McCann,
Rickes et al. 2005) evaluating firocoxib in experimentally induced
pyrexia, demonstrated that the drug was effective after a single
oral dose in preventing or attenuating pyrexia at all doses studied
(0.75 – 3 mg/kg).
Check Digit Verification of cas no
The CAS Registry Mumber 189954-96-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,9,9,5 and 4 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 189954-96:
(8*1)+(7*8)+(6*9)+(5*9)+(4*5)+(3*4)+(2*9)+(1*6)=219
219 % 10 = 9
So 189954-96-9 is a valid CAS Registry Number.
InChI:InChI=1/C17H20O5S/c1-17(2)14(12-6-8-13(9-7-12)23(3,19)20)15(16(18)22-17)21-10-11-4-5-11/h6-9,11H,4-5,10H2,1-3H3
189954-96-9Relevant articles and documents
Preparation method of firocoxib
-
, (2019/10/01)
The invention relates to a preparation method of firocoxib. According to the method, specifically, methylsulfonyl is introduced in the last step of a coupling reaction, and therefore the defect of using thioethers as a starting material (or an intermediate) is avoided.
Preparation method of ferocoxib
-
, (2019/11/28)
The invention relates to the technical field of medicines, in particular to a preparation method of ferocoxib. According to the preparation method, use of volatile heavy-odor raw material thioanisoleis avoided, and use of volatile high-corrosion heavy-odor isobutyryl chloride is avoided, so that environmental protection advantages are obvious; a hydroxyl compound is used for preparing a compoundwith a structure shown in a formula VI, so that use of liquid bromine with high volatility, high toxicity and high corrosivity can be avoided; a compound with a structure shown in a formula V, acetoxyacetyl chloride, an alkali and an organic solvent are mixed for carrying out an esterification reaction to obtain a compound with a structure shown in a formula VI, so that use of cyclopropoxy aceticacid which cannot be industrially produced on a scale is avoided, and then the process is easier to popularize. A test result shows that the preparation method of ferocoxib is more green and environmentally friendly, is more suitable for industrial popularization, and is far superior to the prior art.
Non-luo kaoxi intermediate preparation method (by machine translation)
-
Paragraph 0061; 0062; 0063; 0064; 0065; 0066, (2019/06/08)
The invention relates to a preparation method of the midbody non-luo kaoxi, belongs to the technical field of pharmacy. The invention provides a preparation method includes: a raw material first after the reaction with the acyl chloride reagent, with in addition a raw material in the presence of a reaction, after treatment, to obtain the target product. The method of the invention can be the operability is strong, is beneficial to the industrial production of operation and cost control. (by machine translation)